肝纤维化与原发性脑出血血肿周围水肿增长的关系
本研究为回顾性队列研究,使用虚拟国际卒中试验档案-脑出血(Virtual International Stroke Trials Archive-ICH)数据,纳入症状发作6小时内的成人原发性脑出血患者,评估肝纤维化指数FIB-4评分(连续变量)与96小时血肿周围水肿(PHE)绝对增长的关系。在354例患者中,8%基于已验证截断值存在肝纤维化证据。FIB-4评分在未调整(β=0.03,95%CI -0.01至0.12)和调整模型(β=0.04,95%CI -0.03至0.13)中均与PHE增长无关;将FIB-4作为分类变量比较有无肝纤维化患者,亦未发现PHE增长差异。FIB-4评分与入院时及96小时绝对PHE体积也无关。结论认为,肝纤维化评分与PHE体积或增长无关。
要点
- 在354例原发性脑出血患者中,8%基于已验证截断值存在肝纤维化证据。
- FIB-4评分作为连续变量与96小时PHE绝对增长无关:未调整β=0.03(95%CI -0.01至0.12),调整后β=0.04(95%CI -0.03至0.13)。
- 将FIB-4作为分类变量,有肝纤维化患者与无肝纤维化患者相比,PHE增长无显著差异。
- FIB-4评分与入院时及96小时绝对PHE体积均无关。
- 该多中心队列结果提示,肝纤维化评分不能用于预测原发性脑出血后血肿周围水肿的进展。
适用人群与场景
- 成人原发性脑出血患者,症状发作6小时内就诊。
诊断标准与关键阈值
- 暴露指标为FIB-4评分,一种已验证的肝纤维化指数,作为连续变量分析;二次分析中作为分类变量,以已验证截断值定义肝纤维化。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用虚拟国际卒中试验档案-脑出血(Virtual International Stroke Trials Archive-ICH)数据。
- 样本量:354例脑出血患者,其中8%基于已验证截断值存在肝纤维化证据。
- 主要终点:96小时PHE绝对增长;FIB-4评分与PHE增长无关:未调整模型β=0.03(95%CI -0.01至0.12),调整模型β=0.04(95%CI -0.03至0.13)。
- 次要终点:入院时和96小时绝对PHE体积;FIB-4评分与两者均无关。
- 二次分析:将FIB-4作为分类变量,有肝纤维化患者与无肝纤维化患者相比,PHE增长无显著差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在此多中心原发性脑出血队列中,肝纤维化评分与PHE体积或增长无关。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Liver disease is associated with altered serum osmolality, increased thrombin generation, and systemic inflammation, all of which may contribute to perihematomal edema (PHE) after intracerebral hemorrhage (ICH). We evaluated the association between a validated liver fibrosis index and PHE growth in a cohort of patients with primary ICH.
METHODS: We performed a retrospective cohort study using data from the Virtual International Stroke Trials Archive-ICH. We included adult patients with primary ICH presenting within 6 h of symptom onset. The exposure of interest was the Fibrosis-4 (FIB-4) score, a validated liver fibrosis index; this was modeled as a continuous variable. The primary outcome was absolute PHE growth over 96 h. Secondary outcomes were absolute admission and 96-h PHE volumes. We used multiple linear regression models adjusted for established determinants of PHE. In a secondary analysis, the FIB-4 score was modeled as a categorical variable to compare patients with versus without liver fibrosis.
RESULTS: Among 354 patients with ICH, 8% had evidence of liver fibrosis based on a validated cutoff. The FIB-4 score was not associated with PHE growth in unadjusted (β, 0.03; 95% CI, - 0.01 to 0.12) or adjusted models (β, 0.04; 95% CI, - 0.03 to 0.13). In a secondary analysis treating FIB-4 as a categorical variable, patients with liver fibrosis did not have greater PHE growth than those without liver fibrosis. FIB-4 score was also not associated with absolute admission or 96-h PHE volumes.
CONCLUSIONS: In a multicenter cohort of patients with primary intracerebral hemorrhage, a liver fibrosis score was not associated with PHE volume or growth.
参考来源
- Parikh NS, Jesudian A, Kamel H, et al. Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage. Neurocrit Care. 2020. PMID: 32808155. doi:10.1007/s12028-020-01081-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。